HEPATOCELLULAR CARCINOMA

National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer

Retrieved on: 
Wednesday, December 1, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MTL-CEBPA, atezolizumab and bevacizumab, hepatocellular carcinoma, the National University Hospital, National University Cancer Institute, Singapore, MiNA Therapeutics, MTL-CEBPA, ATEZOLIZUMAB AND BEVACIZUMAB, HEPATOCELLULAR CARCINOMA, THE NATIONAL UNIVERSITY HOSPITAL, NATIONAL UNIVERSITY CANCER INSTITUTE, SINGAPORE, MINA THERAPEUTICS

The study will be conducted at NCISs clinical trial facility with the Haematology-Oncology Research Group (HORG) at the National University Hospital, Singapore.

Key Points: 
  • The study will be conducted at NCISs clinical trial facility with the Haematology-Oncology Research Group (HORG) at the National University Hospital, Singapore.
  • We are excited to evaluate investigational agent MTL-CEBPA in combination with the current standard of care and we are glad to collaborate with MiNA Therapeutics and Roche.
  • Nagy Habib, Head of R&D at MiNA Therapeutics, commented:
    We are delighted to collaborate with the National University Cancer Institute, Singapore, and Roche to evaluate this new immunotherapy combination.
  • MTL-CEBPA is currently in clinical development as a combination therapy for the treatment of advanced liver cancer and advanced solid tumour malignancies.

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

Retrieved on: 
Monday, September 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, KEYNOTE-394, Hepatocellular Carcinoma, KEYTRUDA® (pembrolizumab) Injection, 100 mg, Merck, KEYNOTE-394, HEPATOCELLULAR CARCINOMA, KEYTRUDA® (PEMBROLIZUMAB) INJECTION, 100 MG, MERCK

Hepatocellular carcinoma, which is often diagnosed at an advanced stage, has a five-year survival rate of less than 15%.

Key Points: 
  • Hepatocellular carcinoma, which is often diagnosed at an advanced stage, has a five-year survival rate of less than 15%.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

Retrieved on: 
Wednesday, June 23, 2021
Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Health effects of tobacco, Lung cancer, Cancer treatments, Oncology, Infectious causes of cancer, Head and neck cancer, Chemotherapy, Non-small-cell lung carcinoma, Esophageal cancer, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, NON-SMALL CELL LUNG CANCER, HEPATOCELLULAR CARCINOMA, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

The pivotal clinical program of tislelizumab has seen tremendous progress lately, including two positive Phase 3 trials, one in esophageal cancer and the other in nasopharyngeal cancer.

Key Points: 
  • The pivotal clinical program of tislelizumab has seen tremendous progress lately, including two positive Phase 3 trials, one in esophageal cancer and the other in nasopharyngeal cancer.
  • NSCLC comprises the most common form of lung cancer, although diagnoses are usually delayed with most patients diagnosed at advanced stage.
  • A total of 334 patients in China were enrolled in the trial, randomized 2:1 to either the tislelizumab and chemotherapy arm or the chemotherapy arm.
  • Available at https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-she... ; accessed March 2021.
    iii U.S National Institute of Health (NIH) National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER) Cancer Stat Facts.